A large VHA real-world analysis compared GLP‑1 receptor agonists (~132,000) with sulfonylureas (>201,000), focusing on major adverse cardiovascular outcomes in type 2 diabetes. Continuous GLP‑1 exposure …
Source link
Heart Benefits of GLP-1 Medications Fade Shortly After Stopping Therapy | AJMC
